ArticleFrontiers in medicine2025
Non-alcoholic fatty liver disease is associated with a higher risk of erectile dysfunction than alcoholic fatty liver disease.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: In this study, we examine the prevalence and risk of erectile dysfunction (ED) by conducting a comparative analysis between cohorts with alcoholic fatty liver disease (AFLD) and non-alcoholic fatty liver disease (NAFLD). Methods: This retrospective cohort study used the TriNetX database, including anonymized electronic health records from about 190 million patients globally. The study enrolled men aged ≥20 years diagnosed with AFLD or NAFLD between 2011 and 2019. Patients with liver cirrhosis or malignancy were excluded. Propensity score matching controlled for demographics and comorbidities. The primary outcome, incidence of ED, was analyzed at 1, 3 and 5 years using risk ratios (RR), odds ratios (OR) and hazard ratio (HR), ensuring balanced comparisons. Results: There were 9,066 AFLD and 431,064 NAFLD patients were enrolled before propensity score matching. Finally, following matching, 9,066 patients from each group were included for analysis. Within 1 year, NAFLD patients showed higher ED risk (2.394%) compared to AFLD patients (1.836%), with RR of 1.284 (1.052, 1.567), OR of 1.291 (1.054, 1.582) and HR of 1.263 (1.033, 1.544). At 3 years, NAFLD outcomes remained higher (5.228 vs. 4.169%), RR of 1.254 (1.099, 1.431), OR of 1.268 (1.104, 1.456) and HR of 1.221 (1.066, 1.397). By 5 years, NAFLD continued exhibiting greater risks (6.806 vs. 5.824%), RR of 1.169 (1.044, 1.308), OR of 1.181 (1.047, 1.331) and HR of 1.125 (1.002, 1.264). These findings demonstrate consistently elevated clinical risk in NAFLD patients vs. AFLD, highlighting the necessity of careful NAFLD monitoring. Conclusion: NAFLD demonstrates a significantly greater association with ED than AFLD. Clinicians should maintain heightened vigilance for ED when managing patients with NAFLD, particularly during the initial year following diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.